FEMALE SEXUAL DYSFUNCTION
Female sexual dysfunction affect up to 43% of women causing a "distress" or a psychological strain for the patients. A variety of chronic diseases in addition to menopause and different drugs represents the risk factors to a female sexual dysfunction. Since 2015 the FDA has approved Fliban...
Main Authors: | C. DADAK, M. BAYERLE-EDE |
---|---|
Format: | Article |
Language: | Russian |
Published: |
IRBIS LLC
2016-06-01
|
Series: | Акушерство, гинекология и репродукция |
Subjects: | |
Online Access: | https://www.gynecology.su/jour/article/view/185 |
Similar Items
-
Hypoactive Sexual Desire Disorder - entity and therapeutic approaches: An overview
by: C. da Costa Campos, et al.
Published: (2021-09-01) -
Management of Hypertension with Female Sexual Dysfunction
by: Qing Zhong, et al.
Published: (2022-05-01) -
Flibanserin: A controversial drug for female hypoactive sexual desire disorder
by: Rashmi Baid, et al.
Published: (2018-01-01) -
New developments in the treatment of hypoactive sexual desire disorder – a focus on Flibanserin
by: Jayne CJ, et al.
Published: (2017-04-01) -
Effects of Flibanserin on Subdomain Scores of the Female Sexual Function Index in Women With Hypoactive Sexual Desire Disorder
by: James A. Simon, MD, et al.
Published: (2022-12-01)